Published date: 13-Nov-2021
Source: Eskayef Pharmaceuticals Ltd.

Molnupiravir to be a game changer: Physicians

Source: Eskayef Pharmaceuticals Ltd.

Eskayef Pharmaceuticals Limited, one of the leading drug manufacturing companies of Bangladesh has launched world’s 1st Approved Oral Anti-COVID medicine Molnupiravir with the brand name Monuvir in the form of 200mg capsule. Monuvir is now available in different hospitals, institutions and drug stores all over Bangladesh to be dispensed as per doctor’s prescription.

World’s one of the stringent drug regulatory authorities, UK MHRA authorizes Molnupiravir as the first oral antiviral for the treatment of COVID-19. Eskayef is manufacturing Molnupiravir from its UK MHRA approved state-of-the-art plant.

Eskayef's formulation scientists began working on Monuvir from 2020. After completing all development and manufacturing procedures, Eskayef has received Emergency Use Authorization from Directorate General of Drug Administration (DGDA) of Bangladesh.

Today in presence of renowned physicians of Bangladesh including Prof. Dr. Md. Nazmul Islam, Director, CDC, DGHS, Prof. Dr. Md Robed Amin, Line Director, NCDC, DGHS, Prof. Dr. Billal Alam, President, Bangladesh Society of Medicine, Eskayef has launched Monuvir.

In the launching program Ms. Simeen Rahman, Managing Director and CEO of Eskayef Pharmaceuticals Limited, says, “When the entire world is waiting for an oral anti-COVID medicine, we are very happy to launch Monuvir as the world’s first generic Molnupiravir brand from our UK MHRA approved manufacturing plant for the people of Bangladesh and across the world.” She has also added, “Eskayef will be launching all possible medicines to fight against COVID-19 in our mission of serving the humanity.”

Molnupiravir is indicated for the treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. In Phase III clinical trials occurred in 170 clinical sites in different parts of the world, viral load of positive SARS-COV-2 patients became zero within 5 days after taking Molnupiravir and thus has been regarded as the gamechanger in the fight against COVID-19.